← Back to Search

Atypical Antipsychotic

Iloperidone for Schizophrenia

Phase 1
Waitlist Available
Research Sponsored by Vanda Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights

Study Summary

This study is evaluating whether a new form of a medication may help treat schizophrenia.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Assessment of safety and tolerability of repeat-dosing of iloperidone given as a long-acting injection.
Pharmacokinetics of iloperidone and its metabolites following repeat-dosing of iloperidone given as a long-acting injection.

Side effects data

From 2014 Phase 4 trial • 20 Patients • NCT01464229
46%
Dry Mouth
15%
Nausea
15%
Somnolence
15%
Headaches
8%
Cramping
8%
Palpitations
8%
Increased Irritability
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Iloperidone

Trial Design

1Treatment groups
Experimental Treatment
Group I: IloperidoneExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Iloperidone
2015
Completed Phase 4
~1560

Find a Location

Who is running the clinical trial?

Vanda PharmaceuticalsLead Sponsor
61 Previous Clinical Trials
19,362 Total Patients Enrolled
5 Trials studying Schizophrenia
1,428 Patients Enrolled for Schizophrenia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia
2021. "A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04712734.
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top